CPT® (CDT codes and descriptions are copyright American Dental Association) | |
---|---|
86900 | |
ICD-10-CM | |
C58 | Malignant neoplasm of placenta |
D61.81 | Pancytopenia |
Antiphospholipid antibody with hemorrhagic disorder. D68.312 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM D68.312 became effective on October 1, 2018.
2021 ICD-10-CM Diagnosis Code D80.3 Selective deficiency of immunoglobulin G [IgG] subclasses 2016 2017 2018 2019 2020 2021 Billable/Specific Code D80.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Raised antibody titer 2016 2017 2018 2019 2020 2021 Billable/Specific Code R76.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM R76.0 became effective on October 1, 2020.
Other specified abnormal immunological findings in serum. 2016 2017 2018 2019 2020 2021 Billable/Specific Code. R76.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM R76.8 became effective on October 1, 2020.
Cyclic Citrullinated Peptide (CCP) Antibody (IgG) - A synthetic circular peptide containing citrulline called CCP IgG (cyclic citrullinated peptide) has been found to be better at discriminating Rheumatoid Arthritis patients from patients with other diseases such as hepatitis C infection.
Cyclic Citrullinated Peptide (CCP) Antibody, IgG/IgA (LAB001584)Performed:Twice a week on Wednesdays and FridaysLab:Antiphospholipid Standardizatin Laboratory CLIA 45D107321Synonyms:Anti CCP, Anti-CCP, anti-Cyclic Citrullinated Peptide (CCP) Antibody, IgG/IgACPT 4 Code:8620013 more rows
Doctors use the anti-CCP antibody test in combination with other tests and symptoms to diagnose rheumatoid arthritis and determine the likely course of the disease. Testing positive for anti-CCP antibodies increases the risk of developing a more aggressive form of rheumatoid arthritis.
Circulating IgG anti-cyclic citrullinated peptide antibodies (CCP) are highly specific for rheumatoid arthritis (RA) and prognostic of poor outcome. Serum IgA anti-CCP occurs in a subset of IgG-positive cases and relates to still more aggressive disease.
164914: Anti-CCP (Cyclic Citrullinated Peptide) Antibodies, IgG and IgA, ELISA | Labcorp.
Anti-cyclic citrullinated peptides (anti-CCP) are a type of autoantibody: an antibody that works againstyour body's normal antibodies. Anti-CCP is commonly produced when you have rheumatoid arthritis. These autoantibodies begin targeting and attacking otherwise healthy tissue.
The CCP (cyclic citrullinated peptide) antibody test measures CCP antibodies in the blood. CCP antibodies are proteins that are part of an immune system attack on healthy tissues and cells, such as the joints. A healthcare provider may order this test to help diagnose rheumatoid arthritis (RA).
Conclusion: Anti-CCP is highly specific for the diagnosis of RA. High positive predictive value should be taken into consideration for effective treatment.
Chinese Communist Party, officially the Communist Party of China.
A cyclic citrullinated peptide (CCP) antibody test may be ordered along with or following a rheumatoid factor (RF) test to help diagnose rheumatoid arthritis (RA) and to assess the severity and probable course of the disease (prognosis).
Anticyclic citrullinated peptide The normal level of anti-CCP is less than 20 Units. (At Hospital for Special Surgery, anti-CCP is reported in Units. Some labs report this same result using a different measurement notation, that is, as less than 20 EU/ml.) A level above 20 suggests the possibility of RA.
A positive result for cyclic citrullinated peptide (CCP) antibodies may be suggestive of rheumatoid arthritis (RA) if compatible clinical features of disease are present. Significantly elevated levels of CCP antibodies may be useful to identify RA patients with erosive joint disease.
The 2022 edition of ICD-10-CM D80.6 became effective on October 1, 2021.
D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
The 2022 edition of ICD-10-CM D80.3 became effective on October 1, 2021.
D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
The 2022 edition of ICD-10-CM B96.0 became effective on October 1, 2021.
Bacterial and viral infectious agents. Approximate Synonyms. Mycoplasma infection. Mycoplasma related disease. Pneumonia due to pleuropneumonia like organism.